Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: A nested case-control study

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 626-635

  Kovari, Helen ^a,f   Ledergerber, Bruno ^a   Peter, Ulrich ^b   Flepp, Markus ^c   Jost, Josef ^c   Schmid, Patrick ^d   Calmy, Alexandra ^e   Mueller, Nicolas J ^a   Muellhaupt, Beat ^b   Weber, Rainer ^a  

^a Divisions of Infectious Diseases and Hospital Epidemiology   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c KLINIK IM PARK   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER BIOPSY; LIVER CIRRHOSIS; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTE COUNT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DIDANOSINE; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; MALE; MIDDLE AGED;

EID: 67651086987     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603559     Document Type: Article

References (33)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-9.
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study Arch Intern Med 2006; 166:1632-41.
4. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006; 44:S132-9.
5. Maida I, Nunez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-82.
6. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyper- plasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-92.
7. Arey B, Markov M, Ravi J, Prevette E, Batts K, Nadir A. Nodular regenerative hyperplasia of liver as a consequence of ART. AIDS 2007; 21:1066-8.
8. Sandrine PF, Sylvie A, Andre E, Abdoulaye D, Bernard L, Andre C. Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect? AIDS 2007; 21:1498-9.
9. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet et al: nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21: 1494-5.
10. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-40.
11. MaidaI, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? prevalence, predictors and outcome. Antivir Ther 2008; 13:103-7.
12. Tateo M, Sebagh M, Bralet MP, et al. A new indication for liver transplantation: nodular regenerative hyperplasia in human immunodeficiency virus-infected patients. Liver Transpl 2008; 14:1194-8.
13. Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167-9.
14. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994; 39:387-94.
15. Taffe P, May M. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. Stat Med 2008;27: 4835-53.
16. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366:1059-62.
17. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123:1702-4.
18. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12: 1106-10.
19. Hillaire S, Bonte E, Denninger MH, et al. Idiopathic noncirrhotic intrahepatic portal hypertension in the West: a reevaluation in 28 patients. Gut 2002; 51:275-80.
20. Ibarrola C, Colina F. Clinicopathological features of nine cases of non- cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology 2003; 42:251-64.
21. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787-97.
22. Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11:627-34.
23. Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in noncirrhotic portal hypertension of unknown aetiology. Histopathol- ogy 1996; 28:195-204.
24. Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44:7-14.
25. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-73.
26. Carr A, Morey A, Mallon P, Williams D, Thorburn DR. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV- 1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 2001; 357:1412-4.
27. De Bruyne R, Portmann B, Samyn M, et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 2006; 44:407-10.
28. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse-tran- scriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-26.
29. Use of nucleoside reverse-transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-24.
30. Mallet VO, Bralet MP, Pol S. Response to Schiano et al: hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2008; 103:808-9.
31. Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease? a systematic review. Neth J Med 2005; 63:129-36.
32. Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15: 311-20.
33. Recusani F, Di Matteo A, Gambarin F, D'Armini A, Klersy C, Campana C. Clinical and therapeutical follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients. AIDS 2003; 17(Suppl 1):S88-95.